

17th May 2019

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: USFDA post-approval inspection completed at Cipla's Indore manufacturing facility

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the United States Food and Drug Administration (USFDA) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019. The inspection ended with zero observations.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For Cipla Limited



Rajendra Chopra
Company Secretary & Compliance Officer



Prepared by: Karan Tanna